vs
CoStar Group（CSGP）与Medpace Holdings, Inc.（MEDP）财务数据对比。点击上方公司名可切换其他公司
CoStar Group的季度营收约是Medpace Holdings, Inc.的1.3倍（$899.9M vs $708.5M），Medpace Holdings, Inc.净利率更高（19.1% vs 5.2%，领先13.9%），Medpace Holdings, Inc.同比增速更快（32.0% vs 26.9%），Medpace Holdings, Inc.自由现金流更多（$188.1M vs $101.3M），过去两年Medpace Holdings, Inc.的营收复合增速更高（17.7% vs 17.1%）
CoStar Group是1987年成立的美国商业地产服务商，总部位于弗吉尼亚州阿灵顿，业务覆盖北美、欧洲地区，为商业地产行业提供信息、分析及营销解决方案，旗下运营CoStar线上数据库、新闻网站及Apartments.com、Homes.com等多个线上平台。
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
CSGP vs MEDP — 直观对比
营收规模更大
CSGP
是对方的1.3倍
$708.5M
营收增速更快
MEDP
高出5.2%
26.9%
净利率更高
MEDP
高出13.9%
5.2%
自由现金流更多
MEDP
多$86.8M
$101.3M
两年增速更快
MEDP
近两年复合增速
17.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $899.9M | $708.5M |
| 净利润 | $46.5M | $135.1M |
| 毛利率 | 78.6% | — |
| 营业利润率 | 5.5% | 21.6% |
| 净利率 | 5.2% | 19.1% |
| 营收同比 | 26.9% | 32.0% |
| 净利润同比 | -22.2% | 15.5% |
| 每股收益（稀释后） | $0.12 | $4.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSGPMEDP
| Q4 25 | $899.9M | $708.5M | ||
| Q3 25 | $833.6M | $659.9M | ||
| Q2 25 | $781.3M | $603.3M | ||
| Q1 25 | $732.2M | $558.6M | ||
| Q4 24 | $709.4M | $536.6M | ||
| Q3 24 | $692.6M | $533.3M | ||
| Q2 24 | $677.8M | $528.1M | ||
| Q1 24 | $656.4M | $511.0M |
净利润CSGPMEDP
| Q4 25 | $46.5M | $135.1M | ||
| Q3 25 | $-30.9M | $111.1M | ||
| Q2 25 | $6.2M | $90.3M | ||
| Q1 25 | $-14.8M | $114.6M | ||
| Q4 24 | $59.8M | $117.0M | ||
| Q3 24 | $53.0M | $96.4M | ||
| Q2 24 | $19.2M | $88.4M | ||
| Q1 24 | $6.7M | $102.6M |
毛利率CSGPMEDP
| Q4 25 | 78.6% | — | ||
| Q3 25 | 79.3% | — | ||
| Q2 25 | 78.5% | — | ||
| Q1 25 | 79.1% | — | ||
| Q4 24 | 80.1% | — | ||
| Q3 24 | 79.7% | — | ||
| Q2 24 | 80.0% | — | ||
| Q1 24 | 78.5% | — |
营业利润率CSGPMEDP
| Q4 25 | 5.5% | 21.6% | ||
| Q3 25 | -6.1% | 21.5% | ||
| Q2 25 | -3.5% | 20.9% | ||
| Q1 25 | -5.8% | 20.3% | ||
| Q4 24 | 5.6% | 23.4% | ||
| Q3 24 | 3.4% | 21.1% | ||
| Q2 24 | -2.4% | 19.9% | ||
| Q1 24 | -6.5% | 20.4% |
净利率CSGPMEDP
| Q4 25 | 5.2% | 19.1% | ||
| Q3 25 | -3.7% | 16.8% | ||
| Q2 25 | 0.8% | 15.0% | ||
| Q1 25 | -2.0% | 20.5% | ||
| Q4 24 | 8.4% | 21.8% | ||
| Q3 24 | 7.7% | 18.1% | ||
| Q2 24 | 2.8% | 16.7% | ||
| Q1 24 | 1.0% | 20.1% |
每股收益（稀释后）CSGPMEDP
| Q4 25 | $0.12 | $4.65 | ||
| Q3 25 | $-0.07 | $3.86 | ||
| Q2 25 | $0.01 | $3.10 | ||
| Q1 25 | $-0.04 | $3.67 | ||
| Q4 24 | $0.14 | $3.67 | ||
| Q3 24 | $0.13 | $3.01 | ||
| Q2 24 | $0.05 | $2.75 | ||
| Q1 24 | $0.02 | $3.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.6B | $497.0M |
| 总债务越低越好 | $140.0M | — |
| 股东权益账面价值 | $8.3B | $459.1M |
| 总资产 | $10.5B | $2.0B |
| 负债/权益比越低杠杆越低 | 0.02× | — |
8季度趋势，按日历期对齐
现金及短期投资CSGPMEDP
| Q4 25 | $1.6B | $497.0M | ||
| Q3 25 | $1.9B | $285.4M | ||
| Q2 25 | $3.6B | $46.3M | ||
| Q1 25 | $3.7B | $441.4M | ||
| Q4 24 | $4.7B | $669.4M | ||
| Q3 24 | — | $656.9M | ||
| Q2 24 | — | $510.9M | ||
| Q1 24 | — | $407.0M |
总债务CSGPMEDP
| Q4 25 | $140.0M | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $1.0B | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $1.0B | — | ||
| Q1 24 | $1.0B | — |
股东权益CSGPMEDP
| Q4 25 | $8.3B | $459.1M | ||
| Q3 25 | $8.6B | $293.6M | ||
| Q2 25 | $8.6B | $172.4M | ||
| Q1 25 | $8.6B | $593.6M | ||
| Q4 24 | $7.6B | $825.5M | ||
| Q3 24 | $7.5B | $881.4M | ||
| Q2 24 | $7.4B | $763.6M | ||
| Q1 24 | $7.3B | $671.5M |
总资产CSGPMEDP
| Q4 25 | $10.5B | $2.0B | ||
| Q3 25 | $10.8B | $1.8B | ||
| Q2 25 | $10.5B | $1.6B | ||
| Q1 25 | $10.4B | $1.9B | ||
| Q4 24 | $9.3B | $2.1B | ||
| Q3 24 | $9.1B | $2.1B | ||
| Q2 24 | $9.1B | $1.9B | ||
| Q1 24 | $9.0B | $1.8B |
负债/权益比CSGPMEDP
| Q4 25 | 0.02× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.13× | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $162.1M | $192.7M |
| 自由现金流经营现金流 - 资本支出 | $101.3M | $188.1M |
| 自由现金流率自由现金流/营收 | 11.3% | 26.6% |
| 资本支出强度资本支出/营收 | 6.8% | 0.6% |
| 现金转化率经营现金流/净利润 | 3.49× | 1.43× |
| 过去12个月自由现金流最近4个季度 | $123.0M | $681.9M |
8季度趋势，按日历期对齐
经营现金流CSGPMEDP
| Q4 25 | $162.1M | $192.7M | ||
| Q3 25 | $68.2M | $246.2M | ||
| Q2 25 | $146.5M | $148.5M | ||
| Q1 25 | $53.2M | $125.8M | ||
| Q4 24 | $94.6M | $190.7M | ||
| Q3 24 | $100.3M | $149.1M | ||
| Q2 24 | $58.1M | $116.4M | ||
| Q1 24 | $139.6M | $152.7M |
自由现金流CSGPMEDP
| Q4 25 | $101.3M | $188.1M | ||
| Q3 25 | $-5.5M | $235.5M | ||
| Q2 25 | $27.7M | $142.4M | ||
| Q1 25 | $-500.0K | $115.8M | ||
| Q4 24 | $25.2M | $183.0M | ||
| Q3 24 | $40.2M | $138.5M | ||
| Q2 24 | $-14.7M | $103.5M | ||
| Q1 24 | $-237.1M | $147.2M |
自由现金流率CSGPMEDP
| Q4 25 | 11.3% | 26.6% | ||
| Q3 25 | -0.7% | 35.7% | ||
| Q2 25 | 3.5% | 23.6% | ||
| Q1 25 | -0.1% | 20.7% | ||
| Q4 24 | 3.6% | 34.1% | ||
| Q3 24 | 5.8% | 26.0% | ||
| Q2 24 | -2.2% | 19.6% | ||
| Q1 24 | -36.1% | 28.8% |
资本支出强度CSGPMEDP
| Q4 25 | 6.8% | 0.6% | ||
| Q3 25 | 8.8% | 1.6% | ||
| Q2 25 | 15.2% | 1.0% | ||
| Q1 25 | 7.3% | 1.8% | ||
| Q4 24 | 9.8% | 1.4% | ||
| Q3 24 | 8.7% | 2.0% | ||
| Q2 24 | 10.7% | 2.4% | ||
| Q1 24 | 57.4% | 1.1% |
现金转化率CSGPMEDP
| Q4 25 | 3.49× | 1.43× | ||
| Q3 25 | — | 2.22× | ||
| Q2 25 | 23.63× | 1.65× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | 1.58× | 1.63× | ||
| Q3 24 | 1.89× | 1.55× | ||
| Q2 24 | 3.03× | 1.32× | ||
| Q1 24 | 20.84× | 1.49× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSGP
| Co Star | $503.8M | 56% |
| Other | $283.0M | 31% |
| Loop Net | $94.7M | 11% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
